首页> 外文期刊>The Lancet >Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
【24h】

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

机译:辅助化疗中的上部尿路上皮癌(POUT试验):第3阶段,开放标签,随机对照试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background Urothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial carcinomas of the urinary bladder. No international consensus exists on the benefit of adjuvant chemotherapy for patients with UTUCs after nephroureterectomy with curative intent. The POUT (Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer) trial aimed to assess the efficacy of systemic platinum-based chemotherapy in patients with UTUCs.
机译:背景尿路(UTUC)的尿路上皮癌是罕见的,阶段阶段预后较差,而不是尿膀胱的尿路上皮癌。 没有国际共识,就伴有治疗意图伴有UTUCS患者的辅助化疗的促进。 POUT(上部术治疗的上部化疗在上部核癌症中的监测)试验旨在评估ulucs患者系统铂化疗的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号